Evidence map›Paper›PMID 37910505›Full record

ArticleCell reports2023

The hypoxia-regulated ectonucleotidase CD73 is a host determinant of HIV latency.

Hannah S Sperber, Kyle A Raymond, Mohamed S Bouzidi, Tongcui Ma, Silvana Valdebenito, Eliseo A Eugenin, Nadia R Roan, Steven G Deeks, Sandra Winning, Joachim Fandrey and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cell reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Hannah S SperberVitalant Research Institute, San Francisco, CA, USA; Free University of Berlin, Institute of Biochemistry, Berlin, Germany; University of California, San Francisco, San Francisco, CA, USA; University Hospital Essen, Institute for Translational HIV Research, Essen, Germany.
Kyle A RaymondVitalant Research Institute, San Francisco, CA, USA; University of California, San Francisco, San Francisco, CA, USA.
Mohamed S BouzidiVitalant Research Institute, San Francisco, CA, USA; University of California, San Francisco, San Francisco, CA, USA.
Tongcui MaUniversity of California, San Francisco, San Francisco, CA, USA; Gladstone Institutes, San Francisco, CA, USA.
Silvana ValdebenitoThe University of Texas Medical Branch, Galveston, TX, USA.
Eliseo A EugeninThe University of Texas Medical Branch, Galveston, TX, USA.
Nadia R RoanUniversity of California, San Francisco, San Francisco, CA, USA; Gladstone Institutes, San Francisco, CA, USA.
Steven G DeeksUniversity of California, San Francisco, San Francisco, CA, USA.
Sandra WinningUniversity of Duisburg-Essen, Institute for Physiology, Essen, Germany.
Joachim FandreyUniversity of Duisburg-Essen, Institute for Physiology, Essen, Germany.
Roland SchwarzerUniversity Hospital Essen, Institute for Translational HIV Research, Essen, Germany. Electronic address: roland-schwarzer@gmx.de.
Satish K PillaiVitalant Research Institute, San Francisco, CA, USA; University of California, San Francisco, San Francisco, CA, USA. Electronic address: satish.pillai@ucsf.edu.
University of California, San Francisco · USEssen University Hospital · DEThe University of Texas Medical Branch at Galveston · USUniversity of Duisburg-Essen · DEVitalant · USGladstone Institutes · US

Funding

Delaney AIDS Research Enterprise to Cure HIVUM1AI164560 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS, Sharon Ruth Lewin · 2021 to 2026
$32.0M
The Manhattan HIV Brain BankU24MH100931 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MORGELLO, SUSAN · 2013 to 2023
$14.0M
California NeuroAIDS Tissue NetworkU24MH100928 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ACHIM, CRISTIAN L, MOORE, DAVID J · 2013 to 2023
$13.9M
NATIONAL NEUROLOGICAL AIDS BANKU24MH100929 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SINGER, ELYSE J · 2013 to 2023
$12.5M
Texas NeuroAIDS Research CenterU24MH100930 · NIMH · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GELMAN, BENJAMIN B. · 2013 to 2023
$12.1M
Astrocyte connexin43 containing channels amplify CNS dysfunction in NeuroAIDSR01MH096625 · NIMH · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI EUGENIN, ELISEO A · 2012 to 2020
$4.5M
Phenotypic and mechanistic analysis of the in vivo HIV latent reservoir by single-cell technologiesR01AI147777 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROAN, NADIA R · 2019 to 2022
$3.8M
Role of pannexin-1 hemichannels in NeuroAIDSR01NS105584 · NINDS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI EUGENIN, ELISEO A · 2017 to 2021
$3.2M
Metabolic strategies to eliminate CNS Myeloid Viral ReservoirsR01MH128082 · NIMH · UNIVERSITY OF TEXAS MED BR GALVESTON · PI EUGENIN, ELISEO A · 2021 to 2025
$3.1M
Targeting cell-to-cell communication to prevent bystander damage mediated by viral reservoirsR01MH134761 · NIMH · UNIVERSITY OF TEXAS MED BR GALVESTON · PI Eliseo A Eugenin · 2024 to 2026
$2.1M
Elucidating the mechanism of progesterone-induced permissivity in the upperfemale reproductive tractR01AI127219 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROAN, NADIA R · 2016 to 2020
$2.1M
Effects of Human Galectin-9 on the CNS HIV ReservoirR01MH112457 · NIMH · VITALANT · PI NDHLOVU, LISHOMWA C, PILLAI, SATISH KUMAR · 2016 to 2020
$2.0M
NIAID NIH HHS R01 AI064559NIAID NIH HHS R01 AI127219NIAID NIH HHS R01 AI147777NIAID NIH HHS R01 AI150449NIAID NIH HHS R56 AI064559NIAID NIH HHS UM1 AI164560NIMH NIH HHS R01 MH096625NIMH NIH HHS R01 MH112457NIMH NIH HHS R01 MH128082NIMH NIH HHS R01 MH134761NIMH NIH HHS U24 MH100928NIMH NIH HHS U24 MH100929NIMH NIH HHS U24 MH100930NIMH NIH HHS U24 MH100931NINDS NIH HHS R01 NS105584
6 · The paper itself

Abstract

Deciphering the mechanisms underlying viral persistence is critical to achieving a cure for human immunodeficiency virus (HIV) infection. Here, we implement a systems approach to discover molecular signatures of HIV latently infected CD4

Indexed as

HIV-1HIV Infections5'-NucleotidaseAdenosineCD4-Positive T-LymphocytesGPI-Linked ProteinsHumansVirus ActivationVirus LatencyVirus Replication5'-NucleotidaseAdenosineGPI-Linked ProteinsNT5E protein, humanadenosineCD39CD73CP: ImmunologyCP: MicrobiologyeradicationHIV curehypoxiaIL-8lymphoid tissuespersistencereservoir

Identifiers

PMID37910505
PMCPMC10838153
OpenAlexW4388041161

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.